Your browser is no longer supported. Please, upgrade your browser.
BTX BioTime, Inc. daily Stock Chart
BioTime, Inc.
Index- P/E2.35 EPS (ttm)0.43 Insider Own3.90% Shs Outstand148.24M Perf Week-0.97%
Market Cap151.20M Forward P/E- EPS next Y-0.23 Insider Trans0.00% Shs Float141.23M Perf Month-3.77%
Income56.90M PEG- EPS next Q-0.05 Inst Own44.00% Short Float7.52% Perf Quarter-30.14%
Sales5.20M P/S29.08 EPS this Y-107.70% Inst Trans14.96% Short Ratio18.60 Perf Half Y11.51%
Book/sh1.23 P/B0.83 EPS next Y-900.00% ROA39.60% Target Price4.83 Perf Year-41.47%
Cash/sh0.18 P/C5.58 EPS next 5Y- ROE43.00% 52W Range0.66 - 2.13 Perf YTD11.72%
Dividend- P/FCF- EPS past 5Y14.80% ROI38.60% 52W High-52.09% Beta2.79
Dividend %- Quick Ratio3.50 Sales past 5Y2.40% Gross Margin95.00% 52W Low54.55% ATR0.07
Employees76 Current Ratio3.50 Sales Q/Q28.60% Oper. Margin- RSI (14)44.32 Volatility6.61% 7.40%
OptionableYes Debt/Eq0.03 EPS Q/Q159.10% Profit Margin- Rel Volume0.54 Prev Close1.08
ShortableYes LT Debt/Eq0.03 EarningsMay 09 AMC Payout0.00% Avg Volume570.65K Price1.02
Recom1.70 SMA20-1.02% SMA50-10.50% SMA200-22.33% Volume308,383 Change-5.56%
Jun-14-19Resumed Raymond James Mkt Perform
Feb-21-19Initiated H.C. Wainwright Buy $4
Jan-24-19Initiated Maxim Group Buy $3
Dec-11-18Initiated Oppenheimer Outperform $3.50
Feb-02-18Initiated Lake Street Buy $8
Mar-31-17Initiated Raymond James Outperform $6
Sep-23-16Initiated Ladenburg Thalmann Buy
Feb-19-16Initiated Chardan Capital Markets Buy $5
Dec-22-15Initiated Oppenheimer Outperform $10
Dec-19-11Upgrade WBB Securities Buy → Strong Buy $8
Nov-16-11Upgrade WBB Securities Speculative Buy → Buy $6 → $8
Aug-11-11Initiated WBB Securities Speculative Buy $6
Jan-06-11Initiated BioLogic Equity Research Sell $2
Jun-24-19 06:27AM  Should You Be Excited About BioTime, Inc.'s (NYSEMKT:BTX) 35% Return On Equity? Simply Wall St. -5.56%
Jun-17-19 01:23AM  Is Forbuild SAs (WSE:BTX) 16% ROCE Any Good? Simply Wall St.
May-27-19 05:58AM  Edited Transcript of BTX earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-22-19 08:00AM  BioTime Announces Appointment of General Counsel Business Wire
May-15-19 02:06AM  Don't Sell Forbuild SA (WSE:BTX) Before You Read This Simply Wall St. +10.28%
May-14-19 11:23AM  BioTime (BTX) Q1 2019 Earnings Call Transcript Motley Fool -6.14%
May-13-19 09:13AM  Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1 Zacks -5.79%
May-10-19 08:00AM  BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen® Business Wire
May-09-19 06:35PM  BioTime (BTX) Tops Q1 Earnings and Revenue Estimates Zacks
05:30PM  BioTime: 1Q Earnings Snapshot Associated Press
04:05PM  BioTime Reports First Quarter 2019 Financial Results and Provides Business Update Business Wire
May-06-19 08:00AM  BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury Business Wire
May-03-19 08:00AM  BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019 Business Wire
May-02-19 10:32AM  Will BioTime (BTX) Report Negative Q1 Earnings? What You Should Know Zacks
08:00AM  BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting Business Wire
Apr-27-19 11:44AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs Benzinga
Apr-26-19 08:00AM  BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy and Repair Conference Business Wire
Apr-24-19 02:17PM  Did Changing Sentiment Drive BioTime's (NYSEMKT:BTX) Share Price Down A Worrying 58%? Simply Wall St.
Apr-16-19 08:00AM  BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019) Business Wire
Apr-12-19 09:00AM  BioTime (BTX) Upgraded to Strong Buy: Here's What You Should Know Zacks
Apr-02-19 10:38AM  Top Ranked Momentum Stocks to Buy for April 2nd Zacks
Mar-20-19 08:09AM  Edited Transcript of BTX earnings conference call or presentation 14-Mar-19 8:30pm GMT Thomson Reuters StreetEvents
Mar-18-19 08:00AM  BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019 Business Wire -5.78%
Mar-14-19 05:02PM  BioTime: 4Q Earnings Snapshot Associated Press
04:05PM  BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update Business Wire
Mar-11-19 08:00AM  BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company Business Wire +11.45%
Mar-07-19 08:00AM  BioTime to Report Fourth Quarter and Full Year 2018 Financial Results on March 14th, 2019 Business Wire
Mar-04-19 08:00AM  BioTime to Present at the 14Th Annual Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT 2019) on March 10, 2019 Business Wire
Feb-26-19 08:00AM  BioTime to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019) GlobeNewswire
Feb-22-19 07:55AM  Consolidated Research: 2019 Summary Expectations for Walmart, W.R. Grace, BioTime, Genesee & Wyoming, Northrop Grumman, and Versum Materials Fundamental Analysis, Key Performance Indications GlobeNewswire
Feb-14-19 08:00AM  BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias GlobeNewswire
Feb-05-19 09:00AM  Most Intriguing Companies on the New LD Micro Index ACCESSWIRE
Jan-30-19 08:00AM  Today's Research Reports on Trending Tickers: BioTime and Zynerba Pharmaceuticals ACCESSWIRE
08:00AM  BioTime Inc. Affiliate Company OncoCyte Corporation Reports Successful Results With DetermaVu Diagnostic Test for Lung Cancer GlobeNewswire
Jan-09-19 08:00AM  AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity Business Wire
Jan-07-19 08:00AM  BioTime Enters Into Exclusive Agreement With Orbit Biomedical Ltd. to Access Innovative Device for the Sub-Retinal Delivery of OpRegen® Cells for the Treatment of Dry-AMD GlobeNewswire +5.88%
Jan-04-19 08:00AM  BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase GlobeNewswire +6.25%
Jan-02-19 08:00AM  BioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019 Business Wire +13.91%
07:00AM  AgeX Therapeutics to Present at Biotech Showcase 2019 Business Wire
Dec-23-18 11:38AM  BioTime, Inc. (BTX): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-04-18 08:00AM  BioTime Announces Publication of Positive Preclinical Results Utilizing Proprietary HyStem® Platform in Ischemic Stroke Business Wire
Dec-03-18 07:55AM  New Research: Key Drivers of Growth for Q2, BioTime, Verastem, Fair Isaac, Ulta Beauty, and Chimerix Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Nov-29-18 08:00AM  BioTime to Present at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018 Business Wire +20.36%
08:00AM  AgeX Therapeutics, Inc. to Present Keynote Address at Advanced Stem Cell & Regenerative Medicine 2018 Conference Business Wire
07:00AM  AgeX Therapeutics, Inc. Shares Commence Trading on the NYSE American Business Wire
Nov-28-18 08:00AM  BioTime Announces Distribution of AgeX Therapeutics Shares Business Wire
Nov-09-18 04:10PM  Asterias Biotherapeutics Reports Third Quarter Results GlobeNewswire
Nov-08-18 11:35PM  Edited Transcript of BTX earnings conference call or presentation 8-Nov-18 1:30pm GMT Thomson Reuters StreetEvents -5.24%
01:49PM  Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Asterias Biotherapeutics, Inc. (AST) on Behalf of Stockholders and Encourages AST Investors to Contact the Firm GlobeNewswire
07:53AM  What Kind Of Shareholder Owns Most BioTime Inc (NYSEMKT:BTX) Stock? Simply Wall St.
07:11AM  BioTime: 3Q Earnings Snapshot Associated Press
06:35AM  BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company Business Wire
06:30AM  BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update Business Wire
Nov-06-18 04:30PM  BioTime Announces Update to Third Quarter 2018 Financial Results Conference Call Business Wire
Nov-05-18 08:00AM  BioTime Receives Second Installment Payment of $10.8 Million From Juvenescence Ltd. Business Wire
Nov-01-18 11:28AM  Earnings Preview: BioTime (BTX) Q3 Earnings Expected to Decline Zacks +6.67%
Oct-30-18 08:00AM  BioTime to Report Third Quarter 2018 Financial Results on November 8th, 2018 Business Wire
Oct-29-18 08:00AM  BioTime Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting Business Wire -6.57%
Oct-25-18 08:00AM  BioTime Announces November 16, 2018 Record Date and November 28, 2018 Distribution Date for the Distribution of Age-X Therapeutics Shares Business Wire
Oct-23-18 07:45AM  Report: Exploring Fundamental Drivers Behind The Home Depot, uniQure N.V, Catalent, Apple, BioTime, and PDL BioPharma New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-22-18 08:00AM  BioTime to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 28th Business Wire
Sep-27-18 07:00AM  BioTime to Present at the Upcoming Ladenburg Thalmann and MicroCap Conferences Business Wire
Sep-25-18 07:00AM  BioTime to Participate on Industry Perspectives Roundtable at NEI Audacious Goals in Regenerative Medicine Workshop: Pathways for Retinal Cell Replacement Therapies Business Wire
Sep-21-18 07:00AM  BioTime Warrants to Expire on October 1, 2018 Business Wire +6.05%
Sep-18-18 07:00AM  BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer Business Wire
Sep-17-18 01:00AM  BioTime Updates Timeline for Distribution of AgeX Shares to BioTime Shareholders Business Wire
Sep-04-18 09:37AM  Can The Uptrend Continue for BioTime (BTX)? Zacks
06:55AM  BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence Business Wire
Aug-28-18 07:00AM  BioTimes CEO Adi Mohanty and CFO Russell Skibsted to Participate in Upcoming Panel and Conferences Business Wire
Aug-23-18 08:25AM  Research Report Identifies Cloudera, Snap, Social Reality, BioTime, Renewable Energy Group, and Mattel with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Aug-16-18 08:00AM  AgeX Therapeutics Acquires Technology to Regulate Immune Tolerance Business Wire
07:00AM  BioTime to Present Data at the Military Health System Research Symposium Business Wire
Aug-03-18 11:24PM  Edited Transcript of BTX earnings conference call or presentation 2-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-02-18 06:35PM  BioTime (BTX) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:31PM  BioTime: 2Q Earnings Snapshot Associated Press
04:05PM  BioTime Reports Second Quarter Results and Recent Corporate Accomplishments Business Wire
02:30PM  BioTime, Inc. to Host Earnings Call ACCESSWIRE
08:00AM  BioTime to Receive $43 Million From Juvenescence Business Wire
07:00AM  BioTime Announces the Start of an Investigator Initiated Study of Premvia Designed and Conducted by Dr. Gordon H. Sasaki Business Wire
Aug-01-18 06:12PM  BioTime Announces Distribution Ratio for Distribution of AgeX Therapeutics Shares Business Wire -7.31%
Jul-25-18 07:00AM  Data from BioTimes OpRegen® Program to Be Presented at AAO 2018 Business Wire
Jul-23-18 04:12PM  Here's Why BioTime, Inc Rose as Much as 14.3% Today Motley Fool +11.39%
07:00AM  BioTime to Announce Second Quarter 2018 Results on August 2, 2018 Business Wire
Jul-12-18 09:04AM  BioTime (BTX) in Focus: Stock Moves 7.3% Higher Zacks
Jul-11-18 07:00AM  AgeX Therapeutics CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Research, July 12 in New York City Business Wire +7.27%
Jul-10-18 07:00AM  BioTime Announces July 31, 2018 Record Date for the Distribution of AgeX Therapeutics Shares Business Wire
Jun-29-18 07:00AM  BioTime Awarded Grant From the NIH Business Wire
Jun-26-18 04:37AM  Should You Expect Forbuild SA (WSE:BTX) To Continue Delivering An ROE Of 10.89%? Simply Wall St.
Jun-25-18 07:00AM  BioTime Licenses GMP Cell Line to Goliver Therapeutics Business Wire -5.96%
Jun-19-18 07:00AM  Free Technical Research on BioPharmX and Three More Biotech Equities bio ACCESSWIRE
Jun-14-18 11:37AM  June Fundamental Stock Pick: Forbuild SA (WSE:BTX) Simply Wall St.
08:15AM  Detailed Research: Economic Perspectives on Verizon Communications, PayPal, Menlo Therapeutics, iClick Interactive Asia Group, BioTime, and Adobe What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jun-11-18 07:00AM  AgeX Therapeutics Closes on $5 Million Strategic Investment From Juvenescence Business Wire
Jun-08-18 07:00AM  BioTime Announces Submission of Draft Registration Statement for a Proposed Distribution of Its AgeX Shares Business Wire
Jun-05-18 07:00AM  AgeX Therapeutics Appoints John F. Mauldin to Board of Directors Business Wire +5.06%
May-30-18 07:00AM  BioTime to Present at the 8th Annual LD Micro Invitational Business Wire
May-29-18 07:00AM  BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD Business Wire
May-24-18 07:00AM  BioTime Further Expands OpRegen® Clinical Trial in Dry-AMD With the Opening of Two Additional U.S. Sites Business Wire
May-22-18 04:15AM  How Does Forbuild SAs (WSE:BTX) Earnings Growth Stack Up Against Industry Performance? Simply Wall St.
May-17-18 07:00AM  AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Congress, May 18 in London Business Wire
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. The company has collaboration with Orbit Biomedical, Ltd. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Culley Brian MPresident and CEOJan 01Option Exercise0.00100,0000100,000Jan 03 08:35 PM
SKIBSTED RUSSELLChief Financial OfficerDec 18Option Exercise0.0022,500031,859Dec 20 08:40 AM
Patton Stephana EileneGeneral Counsel & SecretaryDec 18Option Exercise0.0027,500043,995Dec 20 08:36 AM
Patton Stephana EileneGeneral Counsel & SecretaryOct 04Option Exercise0.0013,750021,250Oct 09 06:19 PM
SKIBSTED RUSSELLChief Financial OfficerOct 04Option Exercise0.0011,250013,250Oct 09 07:18 PM
WEST MICHAEL DCo-Chief Executive OfficerSep 17Option Exercise0.0010,9380897,696Sep 19 09:38 PM
ANDREWS DEBORAH JDirectorSep 11Buy2.351,6043,76910,000Sep 13 04:17 PM
WEST MICHAEL DCo-Chief Executive OfficerJul 10Option Exercise0.001,5620887,299Jul 12 07:50 PM
MOHANTY ADITYA P.Co-Chief Executive OfficerJul 10Option Exercise0.004,6870103,005Jul 12 07:45 PM